L26/P-282 Impact of Blastocyst Expansion Stage and Morphological Grade on Clinical Pregnancy Outcomes Following Single Embryo Transfer
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.618 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von H.S. Kim und 14 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Do clinical pregnancy rates differ between hatching and hatched blastocysts of identical morphological grades (BB, BC, and CB) in single embryo transfer cycles? Summary answer Hatched blastocysts showed significantly higher clinical pregnancy rates than hatching blastocysts across morphological grades (BB, BC, and CB), indicating added predictive value beyond morphology. What is known already Blastocyst quality is commonly assessed using the Gardner grading system, which evaluates expansion stage, inner cell mass (ICM), and trophectoderm (TE) morphology. While higher morphological grades are associated with improved implantation potential, the independent contribution of blastocyst expansion status—particularly among embryos with identical morphological grades—remains insufficiently characterized. Study design, size, duration This retrospective cohort study included 5,644 single embryo transfer cycles performed between April 2022 and December 2024. Participants/materials, setting, methods Data were collected from single frozen-thawed blastocyst transfer cycles conducted at CHA Fertility Center Seoul Station. Embryos were classified according to morphological grade (BB, BC, CB) and expansion status (hatching vs. hatched). Clinical pregnancy rates were compared between expansion-stage subgroups within each morphological grade using the chi-square test. Main results and the role of chance Across all morphological grades, hatched blastocysts were associated with significantly higher clinical pregnancy rates than hatching blastocysts. In the BB group, the clinical pregnancy rate was 71.7% (1,458/2,034) for hatched blastocysts versus 60.5% (179/296) for hatching blastocysts (p = 0.001). Similar patterns were observed in the BC group (59.8% [1,252/2,094] vs. 41.3% [248/600], p = 0.001) and the CB group (34.8% [160/460] vs. 18.8% [30/160], p = 0.001). These differences are unlikely to be attributable to chance. Limitations, reasons for caution Due to its retrospective nature, the study is limited in its ability to make causal inferences. Additionally, potential confounding factors, such as maternal age, were not fully controlled for. Wider implications of the findings These findings suggest that, when selecting embryos for transfer, blastocyst expansion status should be considered alongside morphological grading. Incorporating the expansion stage into embryo selection strategies may improve implantation outcomes, especially when choosing between embryos of similar quality. Trial registration number No
Zitieren
APA
Kim, H., Park, E., Hwang, S., Lee, J., Sung, S., Yoon, J., Park, S., An, H., Choi, J., Kim, E., Ko, J., Hur, Y., Hwang, Y., Kim, H., & Yoon, T. (2026). L26/P-282 Impact of Blastocyst Expansion Stage and Morphological Grade on Clinical Pregnancy Outcomes Following Single Embryo Transfer. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.618
Vancouver
Kim H, Park E, Hwang S, Lee J, Sung S, Yoon J, et al. L26/P-282 Impact of Blastocyst Expansion Stage and Morphological Grade on Clinical Pregnancy Outcomes Following Single Embryo Transfer. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.618
BibTeX
@article{Kim2026,
author = {Kim, H.S. and Park, E.A. and Hwang, S.N. and Lee, J.Y. and Sung, S. and Yoon, J. and Park, S. and An, H.W. and Choi, J.Y. and Kim, E.J. and Ko, J.J. and Hur, Y.J. and Hwang, Y.I. and Kim, H.O. and Yoon, T.K.},
title = {L26/P-282 Impact of Blastocyst Expansion Stage and Morphological Grade on Clinical Pregnancy Outcomes Following Single Embryo Transfer},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.618}
}
EUVIMED